Febuxostat:a non-purine,selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout

摘要

Febuxostat is a non-purine,selective inhibitor of xanthine oxidase being developed for the management of hyperuricaemia in patients with gout.With febuxostat 10 -120 mg,the pharmacokinetics are linear.No dose adjustment appears to be necessary in those with renal insufficiency or mild-to-moderate hepatic impairment.Febuxostat 10 - 120mg/day rapidly and sustainably reduces serum uric acid by 25 - 70% in uric acid underexcretors and overproducers.Prophylaxis with colchicine or a non-steroidal anti-inflammatory drug can mitigate the gout-flare risk from the rapid urate lowering after febuxostat initiation.Febuxostat is well tolerated,the majority of treatment-related adverse events are transient and mild-to-moderate in severity.Febuxostat can broaden the therapeutic options for urate-lowering therapy in those with gout.